Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia

@article{Singh2011MetaAnalysisOT,
  title={Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia},
  author={Surendra P. Singh and Vidhi Singh},
  journal={CNS Drugs},
  year={2011},
  volume={25},
  pages={859-885}
}
AbstractBackground: Based on the glutamatergic NMDA receptor hypofunction theory of schizophrenia, NMDA receptor modulators (NMDARMs) may have therapeutic potential in the treatment of schizophrenia. Objective: This meta-analysis aimed to evaluate the potential of modulators of the NMDA receptor as adjunctive therapy for schizophrenia, using the results from published trials. Data Sources: A primary electronic search for controlled clinical trials using NMDARMs in schizophrenia was conducted… Expand
NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials.
TLDR
The results indicate that NMDAR-ANTs as adjunctive therapy may improve cognitive function in patients with schizophrenia. Expand
Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials
TLDR
The results indicate that N-methyl-D-aspartate receptor modulators, particularly with glycine, D-serine and sarcosine, are more beneficial than the placebo in treating schizophrenia, and the effects extended to both positive and negative symptoms, when augmented with antipsychotics other than clozapine. Expand
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials
TLDR
This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia. Expand
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.
TLDR
Results indicate that adjunctive NSAIDs for schizophrenia may not benefit patients treated with first-line antipsychotics judged by PANSS total score change, and further controlled studies are needed, especially in first-episode patients. Expand
Adenosine hypothesis in schizophrenia and bipolar disorder: A systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators
TLDR
It is suggested that adenosine modulator adjuvant therapy is more beneficial in overall psychopathology (especially positive symptoms) in schizophrenia and in treating mania episodes of BD in comparison to placebo. Expand
Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials
TLDR
Memantine as an adjunct treatment appears to have significant efficacy in improving negative symptoms in schizophrenia, and the efficacy and safety of adjunctive memantine for bipolar disorder or MDD needs to be further examined. Expand
Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials
TLDR
People with chronic and non-refractory schizophrenia may benefit from the use of sarcosine as an add-on treatment to antipsychotic medication, due to the good tolerability of this compound. Expand
Pharmacological interventions in clozapine-refractory schizophrenia
This thesis focuses on treatment challenges such as severe cognitive impairments, prominent persistent negative symptoms and treatment-resistant positive symptoms. New treatment approaches toExpand
Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
TLDR
This work aimed to provide perspectives for scientists who sought therapeutic strategies for negative symptoms and cognitive dysfunction in schizophrenia based on the NMDAR hypofunction hypothesis and analyzed the unsatisfactory outcomes of these clinical studies according to the improved glutamate hypothesis that has been revealed in animal models. Expand
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
TLDR
The meta-analysis suggests that sarcosine may be associated with treatment effect on overall clinical symptoms in patients with schizophrenia but not cognitive functions. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 201 REFERENCES
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
TLDR
A meta-analysis of all the double-blind, placebo-controlled studies in patients with schizophrenia was performed to examine their efficacy on different symptom domains, the dose-response, the effects of concomitant antipsychotics, and their side effects, revealing that glycine, D-serine and sarcosine are better than D-cycloserine in improving the overall psychopathology. Expand
Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia.
TLDR
The roles of antioxidants in the pathophysiology of schizophrenia, whether the properties of ginkgo can ameliorate symptoms of this illness, and available literature to test this assumption are reviewed are reviewed. Expand
A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia
TLDR
Memantine showed no efficacy as an adjunctive treatment to atypical antipsychotics in schizophrenia patients with residual psychopathology and was associated with a higher incidence of AEs than placebo. Expand
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
TLDR
Glycine-induced augmentation of NMDA receptor-mediated neurotransmission may thus offer a potentially safe and feasible approach for ameliorating persistent negative symptoms of schizophrenia. Expand
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
TLDR
Glycine potentiates NMDA receptor-mediated neurotransmission, indicating that it may serve as an effective therapeutic agent in the treatment of schizophrenia, and is suggested as an additional approach to the pharmacotherapy of negative symptoms and cognitive deficits in schizophrenia. Expand
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
TLDR
A significant improvement with the D-alanine further supports the hypothesis of hypofunction of NMDA neurotransmission in schizophrenia and strengthens the proof of the principle that NMDA-enhancing treatment is a promising approach for the pharmacotherapy of schizophrenia. Expand
Glutamatergic drugs for schizophrenia.
TLDR
Glycine and D-serine may somewhat improve negative symptoms when added to regular antipsychotic medication, but the results were not fully consistent and data are too few to allow any firm conclusions. Expand
Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials.
TLDR
This meta-analysis confirms that clozapine is more effective than conventional neuroleptics in reducing symptoms of patients with both treatment-resistant and nonresistant schizophrenia. Expand
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site
TLDR
The glycine site potentiators may produce efficacy for negative and cognitive symptoms by blocking apoptosis-like neuropathological processes in patients with chronic schizophrenia and thereby can deter progressive deterioration of the disorder. Expand
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis.
TLDR
Antidepressants along with antipsychotic drugs are more effective in treating the negative symptoms of schizophrenia than antipsychotics alone. Expand
...
1
2
3
4
5
...